Duniya SanoStem Inc (SanoStem) Acquires Stemedica Cell Technologies, Inc.
Bakersfield, CA – February 4, 2025 – Stemedica Inc (Stemedica), a global biopharmaceutical company, is pleased to announce the full acquisition of
Uncategorized
Company Initiatives
Stemedica Cell Technologies Appoints Michael K. Steinhauser CEO and Interim Chairman of the Board
SAN DIEGO, California –May 31, 2023. The Board of Directors of Stemedica Cell Technologies, a best-in-class manufacturer of ischemic tolerant stem cells, announced today that it has appointed Michael K. Steinhauser as Chief Executive Officer and Interim Chairman of…
Clinical Trials
Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke
SAN DIEGO, California – January 19, 2023. Stemedica a best-in-class manufacturer of ischemic tolerant, allogeneic mesenchymal stem cells (itMSC), announced today that it has initiated its “PHASE IIB/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,…
Company Initiatives
Darius Anderson To Join Stemedica Board Of Directors
Respected and seasoned business leader, investor and political strategist offers multiple talents to stem cell technologies company SAN DIEGO, March 30, 2022 /PRNewswire/ — Stemedica a San Diego-based…
Publications
Mesenchymal stem cells in the treatment of severe COVID-19
Santosh Kesari1,2*, Gregory C. Kasper3*, Lev Verkh4 , Terese C. Hammond5 , Marla L. Matal3 , Jay W. Hammerling3 , Nikolai Tankovich4 , Adrianus P. Lim3 , Kevin H. Zhao3 , Tifany Juarez1 , Roberta E. Redfern3 , Jaya M. Gill6 , Natsuko Nomura1 , Audrey Hiemer1 , Annie…
Company Initiatives
StemProtein Awarded U.S. Patent for Biodegradable Microneedle Device
Dissolvable Needles Allow Dermis Delivery of Proteins and Large Molecules SAN DIEGO — August 23, 2021 — StemProtein, LLC (a subsidiary of Stemedica a leading manufacturer of physiologically balanced growth factors, exosomes, and…
Clinical Trials
Stemedica Opens Enrollment in Phase II Clinical Trial for COVID-19 A Phase II Study in Patients with Moderate to Severe ARDS Using GMP, Allogeneic, Bone Marrow-Derived, Ischemic-Tolerant Mesenchymal Stem Cells
SAN DIEGO, Aug. 5, 2021 /PRNewswire/ — Stemedica a San Diego-based biotech company…
Company Initiatives
Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19
SAN DIEGO, California, May 24, 2021 – Stemedica a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announced today that it has signed a Licensing Agreement with Pulthera, LLC for the…
Clinical Trials
FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica’s itMSC Therapy for COVID-19 Patients
SAN DIEGO, Calif. — September 28, 2020 — Stemedica Cell has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval for “A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess…
Clinical Trials
Stemedica in the News! ProMedica Researchers Observe Encouraging Outcomes with Use of Allogeneic Stem Cells in COVID-19 Patients
TOLEDO, Ohio, July 28, 2020 – ProMedica today announced the promising results of its new study that evaluated the use of stem cells in the treatment of adult COVID-19 patients. Eight patients elected to participate in a study under Emergency Investigational New Drug…
Clinical Trials
First Covid-19 Patient Treated Under Emergency Use Ind At Providence Saint John’s Health Center Using Stemedica Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells
SANTA MONICA – April 20, 2020 – A single patient, emergency Investigational New Drug (IND) use was cleared by the U.S. Food and Drug Administration for the treatment of severe lung injury due to COVID-19 at the Providence Saint John’s Health Center, Santa Monica,…
Clinical Trials
Stemedica Reports Positive Results from Phase IIa Clinical Trial Using IV Administration of Mesenchymal Stem Cells for Ischemic Stroke
San Francisco, CA – CONGRESS OF NEUROLOGICAL SURGEONS October 19, 2019 – October 23, 2019 – Study sponsor Stemedica a global biotechnology company that uses cGMP manufactured, ischemia-tolerant (itMSCs), bone marrow derived, allogeneic…